Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box only protein 24 (FBXO24) is a member of the F-box protein family that serves as the substrate-recognition component of the SKP1–CUL1–F-box (SCF) E3 ubiquitin ligase complex, mediating K48-linked polyubiquitination and subsequent proteasomal degradation of specific target proteins, including nucleoside diphosphate kinase A (NDPK-A), PRMT6, and LSD1[1][2][3][5]. FBXO24 is prominently expressed in testicular cells, especially round and elongating spermatids, and plays a critical role in sperm development, particularly mitochondrial and flagellum structure, likely affecting male fertility[1][4]. In somatic cells, FBXO24 is implicated in chromatin regulation and suppression of tumorigenesis; its loss can promote cancer cell proliferation, EMT, and stemness via defective degradation of targets such as LSD1 and likely PRMT6[3]. Disease relevance includes its identification as a candidate tumor suppressor gene in diffuse gastric cancer, association with breast cancer, and links to chromosomal deletion syndromes; however, no therapeutic drugs are currently known to target FBXO24 directly[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box only protein 24 (FBXO24).